12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MOB-015: Preliminary Phase II data

Moberg said an analysis of about 50% of the patients in an open-label, Swedish Phase II trial of once-daily topical MOB-015 showed that there is a "low probability that the final results will be sufficient...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >